Bull Case for Anteris: PARADIGM Readouts Could Reprice the Stock
Anteris Technologies could swing materially higher if DurAVR's PARADIGM program delivers positive clinical and regulatory signals. This trade idea lays out a disciplined long with entry, target and stop, time horizon, catalysts, and the downside scenarios that would invalidate the thesis.